دورية أكاديمية
أعرض في EDS

Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression.

التفاصيل البيبلوغرافية
العنوان: Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression.
المؤلفون: Rivera FB; Department of Medicine, Lincoln Medical Center, New York, New York, USA., Lumbang GNO; Cebu Institute of Medicine, Cebu City, Philippines., Gaid DRM; Cebu Institute of Medicine, Cebu City, Philippines., Cruz LLA; University of the Philippines College of Medicine, Manila, Philippines., Magalong JV; University of the Philippines College of Medicine, Manila, Philippines., Bantayan NRB; University of the Philippines College of Medicine, Manila, Philippines., Lara-Breitinger KM; Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA., Gulati M; Department of Cardiology, Barbra Streisand Women's Heart Center, Cedars-Sinai Smidt Heart Institute, Los Angeles, California, USA., Bakris G; Department of Medicine, University of Chicago, Chicago, Illinois, USA.
المصدر: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2024 Jun; Vol. 26 (6), pp. 2209-2228. Date of Electronic Publication: 2024 Mar 20.
نوع المنشور: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Oxford : Wiley-Blackwell, c1999-
مواضيع طبية MeSH: Blood Pressure*/drug effects , Diabetes Mellitus, Type 2*/drug therapy , Diabetes Mellitus, Type 2*/complications , Diabetes Mellitus, Type 2*/blood , Glucagon-Like Peptide-1 Receptor Agonists*/therapeutic use , Hypoglycemic Agents*/therapeutic use, Humans ; Exenatide/therapeutic use ; Exenatide/pharmacology ; Glucagon-Like Peptides/therapeutic use ; Glucagon-Like Peptides/analogs & derivatives ; Immunoglobulin Fc Fragments/therapeutic use ; Liraglutide/therapeutic use ; Randomized Controlled Trials as Topic ; Recombinant Fusion Proteins/therapeutic use
مستخلص: Aim: The cardiovascular benefits provided by glucagon-like peptide-1 receptor agonists (GLP-1RAs) extend beyond weight reduction and glycaemic control. One possible mechanism may relate to blood pressure (BP) reduction. We aim to quantify the BP-lowering effects of GLP1-RAs.
Methods: A comprehensive database search for placebo-controlled randomized controlled trials on GLP-1RA treatment was conducted until December 2023. Data extraction and quality assessment were carried out, employing a robust statistical analysis using a random effects model to determine outcomes with a mean difference (MD) in mmHg and 95% confidence intervals (CIs). The primary endpoint was the mean difference in systolic BP (SBP) and diastolic BP. Subgroup analyses and meta-regressions were done to account for covariates.
Results: Compared with placebo, GLP-1RAs modestly reduced SBP [semaglutide: MD -3.40 (95% CI -4.22 to -2.59, p < .001); liraglutide: MD -2.61 (95% CI -3.48 to -1.74, p < .001); dulaglutide: MD -1.46 (95% CI -2.20 to -0.72, p < .001); and exenatide: MD -3.36 (95% CI -3.63 to -3.10, p < .001)]. This benefit consistently increased with longer treatment durations. Diastolic BP reduction was only significant in the exenatide group [MD -0.94 (95% CI -1.78 to -0.1), p = .03]. Among semaglutide cohorts, mean changes in glycated haemoglobin and mean changes in body mass index were directly associated with SBP reduction.
Conclusion: Patients on GLP-1RA experienced modest SBP lowering compared with placebo. This observed effect was associated with weight/body mass index reduction and better glycaemic control, which suggests that BP-lowering is an indirect effect of GLP-1RA and unlikely to be responsible for the benefits.
(© 2024 John Wiley & Sons Ltd.)
References: ElSayed NA, Aleppo G, Aroda VR, et al. Pharmacologic approaches to glycemic treatment: standards of Care in Diabetes‐2023. Diabetes Care. 2023;46(suppl 1):S140‐S157.
Fu EL, Clase CM, Janse RJ, et al. Comparative effectiveness of SGLT2i versus GLP1‐RA on cardiovascular outcomes in routine clinical practice. Int J Cardiol. 2022;352:172‐179.
Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ. Cardiovascular actions and clinical outcomes with glucagon‐like Peptide‐1 receptor agonists and dipeptidyl Peptidase‐4 inhibitors. Circulation. 2017;136(9):849‐870.
Helmstädter J, Keppeler K, Küster L, Münzel T, Daiber A, Steven S. Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and their cardiovascular benefits‐the role of the GLP‐1 receptor. Br J Pharmacol. 2022;179(4):659‐676.
Andersen A, Lund A, Knop FK, Vilsbøll T. Glucagon‐like peptide 1 in health and disease. Nat Rev Endocrinol. 2018;14(7):390‐403.
Robinson LE, Holt TA, Rees K, Randeva HS, O'Hare JP. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta‐analysis. BMJ Open. 2013;3(1):e001986.
Sun F, Wu S, Guo S, et al. Impact of GLP‐1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta‐analysis. Diabetes Res Clin Pract. 2015;110(1):26‐37.
Zhao X, Huang K, Zheng M, Duan J. Effect of liraglutide on blood pressure: a meta‐analysis of liraglutide randomized controlled trials. BMC Endocr Disord. 2019;19(1):4.
Wu W, Tong HM, Li YS, Cui J. The effect of semaglutide on blood pressure in patients with type‐2 diabetes: a systematic review and meta‐analysis. Endocrine. 2024;83(3):571‐584.
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
Goldkuhle M, Guyatt GH, Kreuzberger N, et al. GRADE concept 4: rating the certainty of evidence when study interventions or comparators differ from PICO targets. J Clin Epidemiol. 2023;159:40‐48.
Sideri S, Papageorgiou SN, Eliades T. Registration in the international prospective register of systematic reviews (PROSPERO) of systematic review protocols was associated with increased review quality. J Clin Epidemiol. 2018;100:103‐110.
Jorsal A, Kistorp C, Holmager P, et al. Effect of liraglutide, a glucagon‐like peptide‐1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)‐a multicentre, double‐blind, randomised, placebo‐controlled trial. Eur J Heart Fail. 2017;19(1):69‐77.
Loganathan J, Cohen AC, Kaloupis GM, et al. A pilot clinical study to evaluate liraglutide‐mediated anti‐platelet activity in patients with type‐2 diabetes (ELAID study). J Diabetes Complications. 2022;36(5):108188.
Kadowaki T, Isendahl J, Khalid U, et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double‐blind, double‐dummy, placebo‐controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2022;10(3):193‐206.
Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double‐blind, double‐dummy, placebo‐controlled, phase 3 trial. Lancet. 2021;397(10278):971‐984.
Gadde KM, Vetter ML, Iqbal N, Hardy E, Öhman P, investigators D‐N‐s. Efficacy and safety of autoinjected exenatide once‐weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: the DURATION‐NEO‐2 randomized clinical study. Diabetes Obes Metab. 2017;19(7):979‐988.
Knop FK, Aroda VR, do Vale RD, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet. 2023;402(10403):705‐719.
Siskind DJ, Russell AW, Gamble C, et al. Treatment of clozapine‐associated obesity and diabetes with exenatide in adults with schizophrenia: a randomized controlled trial (CODEX). Diabetes Obes Metab. 2018;20(4):1050‐1055.
Moretto TJ, Milton DR, Ridge TD, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug‐naive patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled, parallel‐group study. Clin Ther. 2008;30(8):1448‐1460.
Lingvay I, Desouza CV, Lalic KS, et al. A 26‐week randomized controlled trial of Semaglutide once daily versus liraglutide and placebo in patients with type 2 diabetes suboptimally controlled on diet and exercise with or without metformin. Diabetes Care. 2018;41(9):1926‐1937.
Dungan KM, Weitgasser R, Perez Manghi F, et al. A 24‐week study to evaluate the efficacy and safety of once‐weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD‐8). Diabetes Obes Metab. 2016;18(5):475‐482.
Dejgaard TF, Frandsen CS, Hansen TS, et al. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira‐1): a randomised, double‐blind, placebo‐controlled trial. Lancet Diabetes Endocrinol. 2016;4(3):221‐232.
Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double‐blind, randomised placebo‐controlled trial. Lancet. 2019;394(10193):121‐130.
O'Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double‐blind, placebo and active controlled, dose‐ranging, phase 2 trial. Lancet. 2018;392(10148):637‐649.
Lundkvist P, Pereira MJ, Katsogiannos P, Sjöström CD, Johnsson E, Eriksson JW. Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: sustained reductions in body weight, glycaemia and blood pressure over 1 year. Diabetes Obes Metab. 2017;19(9):1276‐1288.
Mosenzon O, Blicher TM, Rosenlund S, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo‐controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7(7):515‐527.
Wilding JPH, Batterham RL, Calanna S, et al. Once‐weekly Semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989‐1002.
Lincoff AM, Brown‐Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389:2221‐2232.
Husain M, Birkenfeld AL, Donsmark M, et al. Oral Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841‐851.
Gill A, Hoogwerf BJ, Burger J, et al. Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double‐blind, placebo‐controlled, randomized pilot study. Cardiovasc Diabetol. 2010;9:6.
Ghanim H, Batra M, Green K, et al. Liraglutide treatment in overweight and obese patients with type 1 diabetes: a 26‐week randomized controlled trial; mechanisms of weight loss. Diabetes Obes Metab. 2020;22(10):1742‐1752.
Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once‐weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double‐blind, randomised, placebo‐controlled, parallel‐group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251‐260.
le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double‐blind trial. Lancet. 2017;389(10077):1399‐1409.
Davies M, Pieber TR, Hartoft‐Nielsen ML, Hansen OKH, Jabbour S, Rosenstock J. Effect of Oral Semaglutide compared with placebo and subcutaneous Semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. Jama. 2017;318(15):1460‐1470.
Smits MM, Tonneijck L, Muskiet MH, et al. Heart rate acceleration with GLP‐1 receptor agonists in type 2 diabetes patients: an acute and 12‐week randomised, double‐blind, placebo‐controlled trial. Eur J Endocrinol. 2017;176(1):77‐86.
Idorn T, Knop FK, Jørgensen MB, et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and end‐stage renal disease: an investigator‐initiated, placebo‐controlled, double‐blind, parallel‐group. Randomized Trial Diab Care. 2016;39(2):206‐213.
Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous Semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. Jama. 2021;325(14):1414‐1425.
Grunberger G, Chang A, Garcia Soria G, Botros FT, Bsharat R, Milicevic Z. Monotherapy with the once‐weekly GLP‐1 analogue dulaglutide for 12 weeks in patients with type 2 diabetes: dose‐dependent effects on glycaemic control in a randomized, double‐blind, placebo‐controlled study. Diabet Med. 2012;29(10):1260‐1267.
Kim SH, Abbasi F, Lamendola C, et al. Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes. Diabetes Care. 2013;36(10):3276‐3282.
Kumarathurai P, Anholm C, Fabricius‐Bjerre A, et al. Effects of the glucagon‐like peptide‐1 receptor agonist liraglutide on 24‐h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease: a randomized, double‐blind, placebo‐controlled, crossover study. J Hypertens. 2017;35(5):1070‐1078.
Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069‐1084.
Ferdinand KC, White WB, Calhoun DA, et al. Effects of the once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension. 2014;64(4):731‐737.
Faber R, Zander M, Pena A, Michelsen MM, Mygind ND, Prescott E. Effect of the glucagon‐like peptide‐1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes—a randomized, single‐blinded, cross‐over pilot study. Cardiovasc Diabetol. 2015;14:41.
Buse JB, Bergenstal RM, Glass LC, et al. Use of twice‐daily exenatide in basal insulin‐treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2011;154(2):103‐112.
Chen WR, Shen XQ, Zhang Y, et al. Effects of liraglutide on left ventricular function in patients with non‐ST‐segment elevation myocardial infarction. Endocrine. 2016;52(3):516‐526.
Kumarathurai P, Sajadieh A, Anholm C, Kristiansen OP, Haugaard SB, Nielsen OW. Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study. Cardiovasc Diabetol. 2021;20(1):12.
Whicher CA, Price HC, Phiri P, et al. The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: results of a pilot randomized, double‐blind, placebo‐controlled trial. Diabetes Obes Metab. 2021;23(6):1262‐1271.
Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. Jama. 2015;314(7):687‐699.
Kuhadiya ND, Dhindsa S, Ghanim H, et al. Addition of liraglutide to insulin in patients with type 1 diabetes: a randomized placebo‐controlled clinical trial of 12 weeks. Diabetes Care. 2016;39(6):1027‐1035.
de Wit HM, Vervoort GM, Jansen HJ, de Grauw WJ, de Galan BE, Tack CJ. Liraglutide reverses pronounced insulin‐associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT). Diabetologia. 2014;57(9):1812‐1819.
Klausen MK, Jensen ME, Møller M, et al. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo‐controlled clinical trial. JCI. Insight. 2022;7(19):e159863.
Mensberg P, Nyby S, Jørgensen PG, et al. Near‐normalization of glycaemic control with glucagon‐like peptide‐1 receptor agonist treatment combined with exercise in patients with type 2 diabetes. Diabetes Obes Metab. 2017;19(2):172‐180.
Miyagawa J, Odawara M, Takamura T, Iwamoto N, Takita Y, Imaoka T. Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide is non‐inferior to once‐daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26‐week randomized phase III study. Diabetes Obes Metab. 2015;17(10):974‐983.
Lundgren JR, Janus C, Jensen SBK, et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med. 2021;384(18):1719‐1730.
Guja C, Frías JP, Somogyi A, et al. Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: the DURATION‐7 randomized study. Diabetes Obes Metab. 2018;20(7):1602‐1614.
Matikainen N, Söderlund S, Björnson E, et al. Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: a single‐centre randomized controlled study. Diabetes Obes Metab. 2019;21(1):84‐94.
Liakos A, Lambadiari V, Bargiota A, et al. Effect of liraglutide on ambulatory blood pressure in patients with hypertension and type 2 diabetes: a randomized, double‐blind, placebo‐controlled trial. Diabetes Obes Metab. 2019;21(3):517‐524.
Pi‐Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11‐22.
Larsen JR, Vedtofte L, Jakobsen MSL, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine or olanzapine‐treated patients with schizophrenia Spectrum disorder: a randomized clinical trial. JAMA Psychiatry. 2017;74(7):719‐728.
Liutkus J, Rosas Guzman J, Norwood P, et al. A placebo‐controlled trial of exenatide twice‐daily added to thiazolidinediones alone or in combination with metformin. Diabetes Obes Metab. 2010;12(12):1058‐1065.
Bojer AS, Sørensen MH, Bjerre J, Gaede P, Vejlstrup N, Madsen PL. Metabolic improvement with short‐term, glucagon‐like peptide‐1 receptor agonist treatment does not improve cardiac diastolic dysfunction in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled trial. Diabetes Obes Metab. 2021;23(10):2374‐2384.
Sandsdal RM, Juhl CR, Jensen SBK, et al. Combination of exercise and GLP‐1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial. Cardiovasc Diabetol. 2023;22(1):41.
Wadden TA, Walsh OA, Berkowitz RI, et al. Intensive behavioral therapy for obesity combined with liraglutide 3.0 mg: a randomized controlled trial. Obesity (Silver Spring). 2019;27(1):75‐86.
Garvey WT, Batterham RL, Bhatta M, et al. Two‐year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083‐2091.
Rosenstock J, Buse JB, Azeem R, et al. Efficacy and safety of ITCA 650, a novel drug‐device GLP‐1 receptor agonist, in type 2 diabetes uncontrolled with Oral Antidiabetes drugs: the FREEDOM‐1 trial. Diabetes Care. 2018;41(2):333‐340.
Mok J, Adeleke MO, Brown A, et al. Safety and efficacy of liraglutide, 3.0 mg, once daily vs placebo in patients with Poor weight loss following metabolic surgery: the BARI‐OPTIMISE randomized clinical trial. JAMA Surg. 2023;158(10):1003‐1011.
Rodbard HW, Lingvay I, Reed J, et al. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized. Controlled Trial J Clin Endocrinol Metab. 2018;103(6):2291‐2301.
Lind M, Hirsch IB, Tuomilehto J, et al. Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI liraglutide trial). BMJ. 2015;351:h5364.
Gullaksen S, Vernstrøm L, Sørensen SS, et al. Separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and perfusion in people with type 2 diabetes: a randomised trial. Diabetologia. 2023;66(5):813‐825.
Dushay J, Gao C, Gopalakrishnan GS, et al. Short‐term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes. Diabetes Care. 2012;35(1):4‐11.
Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double‐blind, placebo‐controlled study. Lancet. 2009;374(9701):1606‐1616.
Armstrong MJ, Barton D, Gaunt P, et al. Liraglutide efficacy and action in non‐alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double‐blinded, randomised, controlled trial. BMJ Open. 2013;3(11):e003995.
Apovian CM, Bergenstal RM, Cuddihy RM, et al. Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. Am J Med. 2010;123(5):468.e9‐468.e17.
Chen WR, Hu SY, Chen YD, et al. Effects of liraglutide on left ventricular function in patients with ST‐segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am Heart J. 2015;170(5):845‐854.
Dejgaard TF, Schmidt S, Frandsen CS, et al. Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin‐pump‐treated patients with type 1 diabetes: the lira pump trial‐a randomized, double‐blinded, placebo‐controlled trial. Diabetes Obes Metab. 2020;22(4):492‐500.
Kumarathurai P, Anholm C, Nielsen OW, et al. Effects of the glucagon‐like peptide‐1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double‐blind placebo‐controlled crossover study. Cardiovasc Diabetol. 2016;15(1):105.
Jenkins DJA, Sahye‐Pudaruth S, Khodabandehlou K, et al. Systematic review and meta‐analysis examining the relationship between postprandial hypotension, cardiovascular events, and all‐cause mortality. Am J Clin Nutr. 2022;116(3):663‐671.
Trahair LG, Horowitz M, Stevens JE, et al. Effects of exogenous glucagon‐like peptide‐1 on blood pressure, heart rate, gastric emptying, mesenteric blood flow and glycaemic responses to oral glucose in older individuals with normal glucose tolerance or type 2 diabetes. Diabetologia. 2015;58(8):1769‐1778.
Trahair LG, Horowitz M, Hausken T, Feinle‐Bisset C, Rayner CK, Jones KL. Effects of exogenous glucagon‐like peptide‐1 on the blood pressure, heart rate, mesenteric blood flow, and glycemic responses to intraduodenal glucose in healthy older subjects. J Clin Endocrinol Metab. 2014;99(12):E2628‐E2634.
McGuire DK, Busui RP, Deanfield J, et al. Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: design and baseline characteristics of SOUL, a randomized trial. Diabetes Obes Metab. 2023;25(7):1932‐1941.
Maselli D, Atieh J, Clark MM, et al. Effects of liraglutide on gastrointestinal functions and weight in obesity: a randomized clinical and pharmacogenomic trial. Obesity (Silver Spring). 2022;30(8):1608‐1620.
Jones KL, Huynh LQ, Hatzinikolas S, et al. Exenatide once weekly slows gastric emptying of solids and liquids in healthy, overweight people at steady‐state concentrations. Diabetes Obes Metab. 2020;22(5):788‐797.
Jalleh RJ, Jones KL, Nauck M, Horowitz M. Accurate measurements of gastric emptying and gastrointestinal symptoms in the evaluation of glucagon‐like Peptide‐1 receptor agonists. Ann Intern Med. 2023;176(11):1542‐1543.
Acosta A, Camilleri M, Shin A, et al. Quantitative gastrointestinal and psychological traits associated with obesity and response to weight‐loss therapy. Gastroenterology. 2015;148(3):537‐546.
Kennedy C, Hayes P, Salama S, Hennessy M, Fogacci F. The effect of Semaglutide on blood pressure in patients without diabetes: a systematic review and meta‐analysis. J Clin Med. 2023;12(3):772.
Fonseca VA, Devries JH, Henry RR, Donsmark M, Thomsen HF, Plutzky J. Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient‐level pooled analysis of six randomized clinical trials. J Diabetes Complications. 2014;28(3):399‐405.
Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo‐controlled trial. Lancet. 2019;394(10193):131‐138.
Ferdinand KC, Dunn J, Nicolay C, Sam F, Blue EK, Wang H. Weight‐dependent and weight‐independent effects of dulaglutide on blood pressure in patients with type 2 diabetes. Cardiovasc Diabetol. 2023;22(1):49.
Wang B, Zhong J, Lin H, et al. Blood pressure‐lowering effects of GLP‐1 receptor agonists exenatide and liraglutide: a meta‐analysis of clinical trials. Diabetes Obes Metab. 2013;15(8):737‐749.
Hu M, Cai X, Yang W, Zhang S, Nie L, Ji L. Effect of hemoglobin A1c reduction or weight reduction on blood pressure in glucagon‐like Peptide‐1 receptor agonist and sodium‐glucose Cotransporter‐2 inhibitor treatment in type 2 diabetes mellitus: a meta‐analysis. J Am Heart Assoc. 2020;9(7):e015323.
Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon‐like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2011;2011(10):CD006423.
Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon‐like peptide‐1 receptor agonists on weight loss: systematic review and meta‐analyses of randomised controlled trials. BMJ. 2012;344:d7771.
Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and Management of High Blood Pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Hypertension. 2018;71(6):1269‐1324.
Moretto TJ, Milton DR, Ridge TD, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug‐naive patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled, parallel‐group study. Clinical Therapeutics. 2008;30(8):1448‐1460.
Buse JB, Bergenstal RM, Glass LC, et al. Use of twice‐daily exenatide in Basal insulin‐treated patients with type 2 diabetes: a randomized, controlled trial. Annals of Internal Medicine. 2011;154(2):103‐112.
Sun F, Wu S, Chai S, Yang Z, Yu K, Zhan S. Impact of Glp‐1RA on heart rate, blood pressure and hypertension among type 2 diabetes: a systematic review and network meta‐analysis. Value Health. 2014;17(7):A719‐A720.
فهرسة مساهمة: Keywords: blood pressure; dulaglutide; exenatide; glucagon‐like peptide‐1 receptor agonists; liraglutide; semaglutide
المشرفين على المادة: WTT295HSY5 (dulaglutide)
9P1872D4OL (Exenatide)
0 (Glucagon-Like Peptide-1 Receptor Agonists)
62340-29-8 (Glucagon-Like Peptides)
0 (Hypoglycemic Agents)
0 (Immunoglobulin Fc Fragments)
839I73S42A (Liraglutide)
0 (Recombinant Fusion Proteins)
53AXN4NNHX (semaglutide)
تواريخ الأحداث: Date Created: 20240320 Date Completed: 20240508 Latest Revision: 20240819
رمز التحديث: 20240820
DOI: 10.1111/dom.15529
PMID: 38505997
قاعدة البيانات: MEDLINE
الوصف
تدمد:1463-1326
DOI:10.1111/dom.15529